TipRanks on MSN

Imugene’s VAXINIA Study: A Potential Game-Changer in Cancer Treatment

Imugene Ltd (($IUGNF)) announced an update on their ongoing clinical study. Imugene Ltd is conducting a Phase I clinical study titled ‘A Phase I, ...
TipRanks on MSN

Imugene’s OASIS Study: A New Hope for Advanced Solid Tumors

Imugene Ltd (($IUGNF)) announced an update on their ongoing clinical study. Imugene Ltd (IUGNF) is currently conducting a Phase I clinical study ...
ascopubs.org

Development of a novel chimeric oncolytic viral platform, CF33 and its derivatives, for peritoneal-directed CF33-OV treatment of gastric cancer peritoneal carcinomatosis.

Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers ...
BioWorld

CF33-hNIS-antiPDL1 shows efficacy in models of gastric cancer peritoneal carcinomatosis

Genetically modified derivatives of the chimeric oncolytic virus (OV) CF33 have previously shown cancer selectivity and oncolytic potency against various solid tumors.